Brugada Syndrome is an abnormal ECG (Right Bundle Branch Block Pattern with coved ST elevation over the right precordial leads of V1-V3), which leads to ventricular fibrillation (VF) and sudden cardiac death (SCD) in patients with structurally normal hearts. It has been recognized as a clinical entity since 1992. Why should all ED physicians know about this entity? Although a rare syndrome, it is often mistaken as a STEMI and more importantly the clinical spectrum can be asymptomatic to SCD.
Who gets Brugada Syndrome?
- Males > Females in a 8 – 10: 1 ratio
- Ages 20 – 40 years (There are case reports of age 2 days all the way up to 84 years)
- Asian > US populations
- Typically occurs at night, when there is a predominance of vagal activity
How common is Brugada Syndrome?
- Worldwide 4 – 12% of all sudden deaths
- Type 1 Brugada occurs in 12/10,000 people 
- Type 2 and 3 Brugada occurs in 58/10,000 people 
- Prevalance of Brugada Pattern ECG: Asia (0.36%), Europe (0.25%), and in the USA (0.03%) 
- ECG pattern can wax and wane, making the true incidence underestimated
What are the types of Brugada Syndrome?
- Type 1, Type 2, and Type 3 from left to right, seen in leads V1, V2, or V3.
- Sodium channel defect that leads to impaired fast upstroke of phase 0 of the action potential
- See Paucis Verbis (PV) card on Brugada syndrome
Where is the most likely arrhythmogenic substrate of Brugada Syndrome?
- Right Ventricular Outflow Tract (RVOT)
- Only cardiac structure lying underneath 2nd and 3rd intercostal spaces
- Brugada pattern may be absent in typical 4th intercostal space of leads V1 – V3
- Some drugs may induce VF/VT and a comprehensive list can be found at http://www.brugadadrugs.org
What is the best way to risk stratify patients with Brugada Syndrome?
- Symptomatic patients with recurrent syncope, agonal respirations at night during sleep, or unknown seizures are at the highest risk of dying
- Asymptomatic patients have an annual cardiac event rate of 0.25%, therefore there is little value in a risk stratification strategy to identify high risk patients
What are the treatment options for Brugada Syndrome?
- Quinidine is the only medication that has shown benefit in prevention of VF and reduction of AICD shocks (Only 67% of patients can tolerate drug due to side effects)
- Implantable Cardiac Defibrillator (ICD): Class 1 Indication in symptomatic patients (past history of VT/VF or syncope)
- Defibrillator Versus B-Blocker in Unexplained Death in Thailand (DEBUT) Trial: Showed 0% death rate after ICD versus 18% in Beta Blocker group 
- Leadless ICDs: 98% termination rate of VF/VT, but less pocket infection and lead revisions 
- Catheter Ablation: Performed in 14 patients with no recurrent VF/VT with a median 32 month follow up 
Image from 
Take home point
Brugada Syndrome is an uncommon entity, that can mimic STEMI, has a high rate of sudden cardiac death, and currently ICD placement is the best treatment strategy.
- [ref id=”11527631″ link=true]
- [ref id=”22715240″ link=true]
- [ref id=”12695290″ link=true]
- [ref id=”23535677″ link=true]
- [ref id=”23142437″ link=true]
- [ref id=”23535677″ link=true]